anastrozole has been researched along with Sex Disorders in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Asymptomatic postmenopausal women who took adjuvant tamoxifen for 2 to 3 years for operable breast cancer with a double endometrial thickness greater than 7 mm were randomized to 20 mg tamoxifen or 1 mg anastrozole for the remaining duration, totaling 5 years." | 5.15 | Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole. ( Amant, F; Berteloot, P; Blomme, C; De Jonge, E; Depypere, H; Neven, P; Timmerman, D; Van Calster, B; Van de Putte, G; Van den Broecke, R; Van Ginderachter, J; Van Huffel, S; Vergote, I; Vlaemynck, G; Vlasselaer, J, 2011) |
| "Most prolactinomas respond rapidly to low doses of dopamine agonists." | 1.31 | The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. ( Freed, DJ; Gillam, MP; Middler, S; Molitch, ME, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kacker, R | 1 |
| Conners, W | 1 |
| Zade, J | 1 |
| Morgentaler, A | 1 |
| Herzog, AG | 1 |
| Farina, EL | 1 |
| Drislane, FW | 1 |
| Schomer, DL | 1 |
| Smithson, SD | 1 |
| Fowler, KM | 1 |
| Dworetzky, BA | 1 |
| Bromfield, EB | 1 |
| Van Calster, B | 1 |
| Van Ginderachter, J | 1 |
| Vlasselaer, J | 1 |
| Van de Putte, G | 1 |
| Berteloot, P | 1 |
| Timmerman, D | 1 |
| Depypere, H | 1 |
| Blomme, C | 1 |
| Vlaemynck, G | 1 |
| De Jonge, E | 1 |
| Van den Broecke, R | 1 |
| Vergote, I | 1 |
| Amant, F | 1 |
| Van Huffel, S | 1 |
| Neven, P | 1 |
| Gillam, MP | 1 |
| Middler, S | 1 |
| Freed, DJ | 1 |
| Molitch, ME | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Anastrozole and Testosterone Versus Placebo and Testosterone Treatment of Reproductive and Sexual Dysfunction in Men With Epilepsy and Hypogonadism[NCT00179517] | Phase 2 | 40 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Bioavailable Testosterone and luteinizing hormone levels were measured once a month over the three month study in the treatment and placebo group. The bioactive testosterone and luteinizing hormone levels were averaged for the three months. The ratio between the average bioactive testosterone level and average luteinizing hormone levels were reported. (NCT00179517)
Timeframe: Assessed for 3 months
| Intervention | Ratio (Mean) |
|---|---|
| Depotestosterone Plus Anastrozole (T-A) | 450.24 |
| Depotestosterone Plus Placebo (T-P) | 482.65 |
Bioavailable testosterone levels were measured at baseline and once a month over the three month study. The average change in bioactive testosterone levels from baseline to the end of the three month study was reported. (NCT00179517)
Timeframe: Assessed for 3 months
| Intervention | ng/dl (Mean) |
|---|---|
| Depotestosterone Plus Anastrozole (T-A) | 150.9 |
| Depotestosterone Plus Placebo (T-P) | 161.7 |
The average change in number of seizures over the 3 month study for the depotestosterone plus anastrozole (T-A) and depotestosterone plus placebo (T-P) were reported. (NCT00179517)
Timeframe: Assessed for 3 months
| Intervention | number of seizures (Mean) |
|---|---|
| Depotestosterone Plus Anastrozole (T-A) | -2.0 |
| Depotestosterone Plus Placebo (T-P) | -2.9 |
Estradiol and luteinizing hormone levels were measured once a month over the three month study in the treatment and placebo group. The estradiol and luteinizing hormone levels were averaged for the three months. The ratio between the average estradiol levels and average luteinizing hormone levels were reported. (NCT00179517)
Timeframe: Assessed for 3 months
| Intervention | Ratio (Mean) |
|---|---|
| Depotestosterone Plus Anastrozole (T-A) | 9.31 |
| Depotestosterone Plus Placebo (T-P) | 53.80 |
Estradiol levels were measured once a month over the three month study in subjects taking anastrozole (T-A) and in subjects taking placebo (T-P). The average change in estradiol levels was reported. (NCT00179517)
Timeframe: Assessed for 3 months
| Intervention | pg/mL (Mean) |
|---|---|
| Depotestosterone Plus Anastrozole (T-A) | -14.6 |
| Depotestosterone Plus Placebo (T-P) | 8.6 |
Bioavailable testosterone and estradiol levels were measured once a month over the three month study in subjects taking anastrozole and subjects taking placebo. The bioavailable testosterone and estradiol levels for the three months were averaged for each subject. The ratio between the average bioavailable testosterone level and average estradiol levels were reported. (NCT00179517)
Timeframe: Assessed for 3 months
| Intervention | Ratio (Mean) |
|---|---|
| Depotestosterone Plus Anastrozole (T-A) | 145.47 |
| Depotestosterone Plus Placebo (T-P) | 12.78 |
Changes in energy, mood and anxiety scores were measured using The Beck Depression Inventory II and the POMS questionnaire. The Beck Depression Inventory II questionnaire consisted of 21 questions, each with answers ranging from 0-3. The answers for each question were summed. The scale ranged from 0-63 with higher scores meaning a higher depression score (worse score). The POMS questionnaire had a total of 65 questions that measured tension, depression, anger, vigor, fatigue and confusion. The total POMS score ranged from 0-200, with lower scores being better. The POMS tension score ranged from 0-36 with lower scores being better. The POMS depression score ranged from 0-60 with lower scores being better. The POMS anger score ranged from 0-48, lower scores being better. The POMS vigor score ranged from 0-32, lower scores being better. The POMS fatigue score ranged from 0-28, lower scores being better. The POMS confusion score ranged from 0-28 with lower scores being better. (NCT00179517)
Timeframe: Assessed for 3 months
| Intervention | Scores on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Change in Depression (Beck Depression Inventory II | Change in Vigor | Change in Fatigue | Change in Depression (POMS-D) | Change in Anxiety (POMS-T) | Change in Anger (POMS A) | Change in Confusion (POMS-C) | |
| Depotestosterone Plus Anastrozole (T-A) | -5.3 | 4.6 | -6.0 | -5.6 | -3.0 | -2.4 | -2.7 |
| Depotestosterone Plus Placebo (T-P) | -6.4 | 4.8 | -4.5 | -6.7 | -4.2 | -2.6 | -2.7 |
S-Scores and Reynolds Questionnaire scores were assessed at baseline and once a month over three months. The average change in score for each questionnaire over the 3 month study was reported. The S-Scores questionnaire measured sexual function and consisted of four questions with five possible answers. The total scale range was 0-20, with higher scores were considered better. S-Scores that were greater than or equal to 16/20 were considered normalized S-Scores. Reynolds Questionnaire is a 21 item survey that monitors sexual interest, activity, satisfaction, and function. The scale for the Reynolds questionnaire for sexual interest was from 0-12, with higher scores being better. The scale for sexual activity was 0-41 with higher scores being better. The sexual satisfaction scale was from 0-21 with higher scores being better. The scale for sexual function was from 0 to -12 with lower scores being better. (NCT00179517)
Timeframe: 3 month average
| Intervention | Scores on a Scale (Mean) | ||||
|---|---|---|---|---|---|
| Change in S-Score | Reynolds Questionnaire Change in R-Interest | Reynolds Questionnaire Change in R-Activity | Reynolds Questionnaire Change in R-Satisfaction | Reynolds Questionnaire Change in R-Function | |
| Depotestosterone Plus Anastrozole (T-A) | 3.7 | 2.4 | 11.1 | 2.4 | -1.7 |
| Depotestosterone Plus Placebo (T-P) | 2.5 | 1.5 | 4.7 | 2.1 | -1.3 |
The proportion of men who achieve normalization of sexual scores (scores greater than or equal to 16/20) on anastrozole (T-A) and those on placebo (T-P) are reported. Both Men who achieve normalization of sexual scores and those who did not achieve normalization of sexual scores were reported for anastrozole (T-A) treatment group and the placebo treatment group. Sexual scores were gathered once per month for three months with the average of the three months reported. (NCT00179517)
Timeframe: Assessed for 3 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Normalization of S-Score | No Normalization of S-Score | |
| Depotestosterone Plus Anastrozole (T-A) | 13 | 5 |
| Depotestosterone Plus Placebo (T-P) | 9 | 10 |
2 trials available for anastrozole and Sex Disorders
| Article | Year |
|---|---|
A comparison of anastrozole and testosterone versus placebo and testosterone for treatment of sexual dysfunction in men with epilepsy and hypogonadism.
Topics: Adolescent; Adult; Anastrozole; Aromatase Inhibitors; Double-Blind Method; Drug Therapy, Combination | 2010 |
Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-B | 2011 |
2 other studies available for anastrozole and Sex Disorders
| Article | Year |
|---|---|
Bone mineral density and response to treatment in men younger than 50 years with testosterone deficiency and sexual dysfunction or infertility.
Topics: Age Factors; Anastrozole; Androgens; Aromatase Inhibitors; Bone Density; Clomiphene; Deficiency Dise | 2014 |
The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.
Topics: Adult; Anastrozole; Aromatase Inhibitors; Bromocriptine; Cabergoline; Dopamine Agonists; Enzyme Inhi | 2002 |